key: cord-0860040-2pkn4awy
authors: Gambichler, T.; Boms, S.; Hessam, S.; Tischoff, I.; Tannapfel, A.; Lüttringhaus, T.; Beckman, J.; Stranzenbach, R.
title: Primary cutaneous anaplastic large cell lymphoma with marked spontaneous regression of organ manifestation after SARS‐CoV‐2 vaccination
date: 2021-07-06
journal: Br J Dermatol
DOI: 10.1111/bjd.20630
sha: b3d4703ea23bc23dbe74afccf301cb5f9239e895
doc_id: 860040
cord_uid: 2pkn4awy

Primary cutaneous anaplastic large cell lymphoma (pcALCL) belongs to the primary cutaneous CD30+ T cell lymphoproliferative disorders.(1) Systemic involvement is relatively rare and rather confined to the regional lymph nodes.(1)We describe a patient with recurrent pcALCL and diffuse lung manifestation which spontaneously regressed after one SARS‐CoV‐2 vaccination. We report a 57‐year‐old male patient with a 10‐year history of biopsy‐proven (CD30+, CD3+, CD4+, ALK‐, clonal T cell receptor gamma chain rearrangement) pcALCL with frequent local relapses predominantly affecting his scalp and neck.

and diffuse lung manifestation which spontaneously regressed after one SARS-CoV-2 vaccination.

We report a 57-year-old male patient with a 10-year history of biopsy-proven (CD30+, CD3+, CD4+, ALK-, clonal T cell receptor gamma chain rearrangement) pcALCL with frequent local relapses predominantly affecting his scalp and neck. Moreover, there was a history of suspicious waning and waxing cervical lymph nodes (partly biopsy-proven) over the last 5 years. Pretreatments included methotrexate, brentuximab, gemcitabine, and radiotherapy. The last treatment (radiotherapy) of cutaneous lesions (Fig. 1a) was performed in February 2021 resulting in complete remission. End of March 2021, ultrasound revealed again a pathologically enlarged cervical lymph node (Fig. 1e) . Thoracic computer tomography (CT) showed innumerable bilateral pulmonal nodules which were suspicious for new pcALCL manifestation or second malignancy ( Fig. 1g) . Bone marrow was not involved. A lung wedge resection was scheduled including a histological confirmation by a haematopathology reference centre. Histolopathology of several lesions of the lung revealed infiltrates of Hodgkin/Reed-Sternberg-like cells which were positive for CD30, CD3, CD4, TGP, CD15 and negative for Bcl-6, EMA, and ALK-1. On multiplex-PCR, there was a monoclonal T cell receptor gamma (tube A: 244 bp) and beta (tube A: 254 bp; tube B: 255 bp) chain rearrangement in the lung tissue which was exactly the same pattern as observed in biopsies of skin lesions 5 and 9 years before. Rechallenge with brentuximab was discussed in the interdisciplinary tumour board. A few days before initiation of brentuximab therapy, the patient noticed shrinking of the suspicious cervical lymph node which was confirmed by means of ultrasound (Fig. 1f) . Moreover, thoracic CT revealed an almost complete resolution of the diffuse lung lesions (Fig. 1h) . Importantly, one week before pcALCL restaging, the patient had received his first COVID-19 vaccination (Comirnaty®, BioNTech/Pfizer, Mainz, Germany).

This article is protected by copyright. All rights reserved pcALCL is a rare lymphoma with an excellent prognosis as indicated by a 10-year survival rate of about 90%. However, the recurrence rate of pcALCL is high. Notably, 10 to 42% of patients diagnosed with pcALCL may experience spontaneous remission. 1 We detected identical clonal T cell receptor gamma chain rearrangements in lung lesions and previous skin lesions, together proving that the pulmonal lesions very likely originated from pcALCL. Eberle et al. 2 demonstrated that systemic manifestations of pcALCL frequently show Hodgkin/Reed-Sternberg-like infiltrates and that the co-expression of CD30 and CD15 in these cases may result in a mistaken diagnosis of classical Hodgkin disease. 2 Diffuse pulmonal disease descending from pcALCL, as described in the present letter, is certainly unusual and spontaneous regression of such a tumour load anyway, even though pcALCL is often associated with spontaneous regression as mentioned before. 1, 2 The most often reported triggers of spontaneous remission of malignancies include surgical trauma, infections, and vaccines. Several vaccines, including smallpox, BCG, tetanus-diphtheriapertussis, rabies, have previously been reported to be associated with spontaneous cancer remission. Accordingly, medical research has focussed for long time on cancer microbial vaccine immunotherapy. 3, 4 Our patient received the COVID-19 vaccination one week before the detection of the almost complete resolution of his currently untreated lymphoma manifestations. After his COVID-19 vaccination, he noticed that the suspicious cervical lymph node regressed, indicating that the remission process likely started after the vaccination. Hence, the temporal sequence strongly suggests but not proves that SARS-CoV2 vaccine was the causal factor of the marked spontaneous regression of organ manifestation observed in the present case.

Dotan et al. 5 proposed that the most likely mechanism to have the potential of contributing to the development of autoimmunity in COVID-19 is the capability of SARS-CoV-2 to overstimulate the immune system as well as the molecular mimicry between self-components of the host and the viral components. There is growing evidence that autoimmunity due to COVID-19 infection can also be triggered by SARS-CoV-2 vaccines. [5] [6] [7] The combination of a genetically predisposed individual with an overstimulated state of the immune system due to SARS-CoV-2 vaccination may trigger autoimmune phenomena/diseases such as myasthenia gravis, Schönlein-Henoch purpura, Rowell's syndrome. [5] [6] [7] We thus speculate that SARS-CoV-2 vaccines have the potential Accepted Article not only to trigger autoimmunity but also may enhance anti-tumour responses due to overstimulation of the immune system. In contrast, Brumfield et al. 8 recently reported on the recurrence of a primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination.

In conclusion, we observed marked spontaneous regression of organ manifestation in a patient with recurrent pcALCL following the first SARS-CoV-2 vaccination. However, as up to 42% of pcALCL may show spontaneous regression, we cannot fully exclude that this occurred also in the present case.

Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review

Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma

Spontaneous regression of malignant melanoma -is it based on the interplay between host immune system and melanoma antigens? Anticancer Drugs

Spontaneous regression of tumour and the role of microbial infection--possibilities for cancer treatment

The SARS-CoV-2 as an instrumental trigger of autoimmunity

Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination. Vaccines (Basel)